Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline vs Sinemet CR for Nocturnal Disability in PD
NCT00174239Phase 4Terminated
- Sponsor
- Pfizer
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 4 trial of cabergoline in Parkinson's disease (PD), sponsored by Pfizer. Started Jul 2004; status: terminated.
02
Drugs
cabergoline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00174239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174239.